Pegloticase

(Kyrstexxa®)

Pegloticase

Drug updated on 10/23/2023

Dosage FormInjection (intravenous; 8 mg/mL)
Drug ClassPEGylated uric acid specific enzyme
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of chronic gout in adult patients refractory to conventional therapy.

Product Monograph / Prescribing Information

Document TitleYearSource
Krystexxa (pegloticase) Prescribing Information.2022Horizon Therapeutics USA, Inc., Deerfield, IL

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines

Document TitleYearSource
2020 American College of Rheumatology guideline for the management of gout.2020American College of Rheumatology